All In Biotech

Drug Trial Radar · NCT06601192

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Phase 1, Randomized, Double-Blind Four-Period Crossover, Thorough QT/QTc Study to Evaluate the Effects of EDP-938 on Cardiac Repolarization in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Jul 15, 2024

Primary completion

Feb 2, 2025

Study completion Feb 25, 2025

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.

Conditions

  • RSV Infection
  • QTc Interval

Interventions

  • zelicapavir (therapeutic dose)Drug

    Subjects will receive zelicapavir (TD) once per treatment period.

  • zelicapavir (supratherapeutic dose)Drug

    Subjects will receive zelicapavir (SD) once per treatment period.

  • PlaceboDrug

    Subjects will receive zelicapavir matching placebo once per treatment period.

  • moxifloxacinDrug

    Subjects will receive moxifloxin once per treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction QTcF (ΔΔQTcF) after TD and SD of ZelicapavirTime frame: Up to 24 hours post dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • ICON

    Lenexa, Kansas

  • ICON Early Phase, LLC

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.